The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations
Crossref DOI link: https://doi.org/10.1007/s10096-015-2538-z
Published Online: 2015-12-12
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Goldenberg, S. D.
Brown, S.
Edwards, L.
Gnanarajah, D.
Howard, P.
Jenkins, D.
Nayar, D.
Pasztor, M.
Oliver, S.
Planche, T.
Sandoe, J. A. T.
Wade, P.
Whitney, L.
Funding for this research was provided by:
Astellas Pharma Europe (GB)
License valid from 2015-12-12